Drugs / 64Cu-Tz-SarAr
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05737615 | Feb 2023 → Feb 2026 | pancreatic ductal adenocarcinoma | Memorial Sloan Kettering Cancer Center | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 64Cu-Tz-SarAr | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05737615 ↗ |
| Modality | Diagnostic / imaging agent | “Pretargeted PET Imaging Using 64Cu-Tz-SarAr” NCT05737615 ↗ |
| Route | Intravenous | “a single slow infusion of 64Cu-Tz-SarAr will be administered intravenously” NCT05737615 ↗ |